Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Sells $42,315.70 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) insider Minardo John sold 9,910 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $4.27, for a total transaction of $42,315.70. Following the transaction, the insider now directly owns 284,661 shares in the company, valued at approximately $1,215,502.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ironwood Pharmaceuticals Stock Down 3.3 %

IRWD opened at $4.34 on Thursday. The firm’s 50 day moving average is $6.18 and its 200-day moving average is $8.38. Ironwood Pharmaceuticals, Inc. has a 52-week low of $3.79 and a 52-week high of $15.70. The firm has a market capitalization of $679.34 million, a P/E ratio of -0.64 and a beta of 0.52.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Eagle Investment Management LLC boosted its position in Ironwood Pharmaceuticals by 11.1% in the 4th quarter. First Eagle Investment Management LLC now owns 907,225 shares of the biotechnology company’s stock valued at $10,379,000 after buying an additional 90,636 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Ironwood Pharmaceuticals by 244.8% in the first quarter. Russell Investments Group Ltd. now owns 777,847 shares of the biotechnology company’s stock worth $6,775,000 after acquiring an additional 552,227 shares in the last quarter. Eventide Asset Management LLC purchased a new position in Ironwood Pharmaceuticals in the fourth quarter valued at about $8,472,000. Norges Bank acquired a new stake in Ironwood Pharmaceuticals during the 4th quarter valued at approximately $9,321,000. Finally, Entropy Technologies LP purchased a new stake in Ironwood Pharmaceuticals during the 1st quarter worth approximately $693,000.

Analyst Ratings Changes

Several brokerages have weighed in on IRWD. Capital One Financial downgraded Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $12.00 to $4.00 in a report on Thursday, August 8th. StockNews.com raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, July 16th. Craig Hallum cut their price objective on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, Wells Fargo & Company reduced their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.00.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.